



October 27, 2026

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400001

**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

**Subject: Outcome of the Board Meeting held on October 27, 2026**

**Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Listing Regulations, and SEBI Master Circular SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. on Tuesday, October 27, 2026, commenced at 11:10 a.m. and concluded at 02:00 p.m., has, *inter-alia*, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 ("Financial Results").

Pursuant to applicable provisions of the Listing Regulations, we enclose the following:

1. A copy of aforesaid Financial Results and
2. Limited Review Report on the Unaudited Financial Results issued by the Statutory Auditors of the Company

The above-mentioned documents will also be available on the Company's website [www.jubilantingrevia.com](http://www.jubilantingrevia.com)

We request you to take the same on record.

Thanking you

Yours faithfully,

**For Jubilant Ingrevia Limited**

**Deepanjali Gulati**  
Digitally signed by  
Deepanjali Gulati  
Date: 2026.10.27 14:01:50  
+05'30'

**Deepanjali Gulati**

**Company Secretary & Compliance Officer**

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Ingrevia Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
Uttar Pradesh, India  
CIN : L24299UP2019PLC122657

**Walker Chandlok & Co LLP**

21<sup>st</sup> Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram- 122002  
India

T +91 120 485 5999  
F +91 120 485 5902

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Jubilant Ingrevia Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025.
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandlok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker Chandiok & Co LLP

### Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

*Modhu Sudan*



**Madhu Sudan Malpani**

Partner

Membership No.: 517440

UDIN: 26517440OIPTVR2188

**Place:** Noida

**Date:** 27 October 2026

**Jubilant Ingrevia Limited**

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

**Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2026**

(₹ in Lakhs)

| Sr. No. | Particulars                                                                        | Quarter Ended |               |               | Half Year Ended |               | Year Ended    |
|---------|------------------------------------------------------------------------------------|---------------|---------------|---------------|-----------------|---------------|---------------|
|         |                                                                                    | 30 September  | 30 June       | 30 September  | 30 September    | 30 September  | 31 March      |
|         |                                                                                    | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Unaudited)     | (Unaudited)   | (Audited)     |
|         |                                                                                    | 2026          | 2026          | 2025          | 2026            | 2025          | 2026          |
| 1       | <b>Revenue from operations</b>                                                     |               |               |               |                 |               |               |
|         | a) Sales/Income from operations                                                    | 121367        | 124233        | 104316        | 245600          | 200771        | 409745        |
|         | b) Other operating income                                                          | 1228          | 1032          | 1102          | 2260            | 1955          | 4104          |
|         | <b>Total revenue from operations</b>                                               | <b>122595</b> | <b>125265</b> | <b>105418</b> | <b>247860</b>   | <b>202726</b> | <b>413849</b> |
| 2       | Other income                                                                       | 977           | 1057          | 1091          | 2034            | 2201          | 9969          |
| 3       | <b>Total income (1+2)</b>                                                          | <b>123572</b> | <b>126322</b> | <b>106509</b> | <b>249894</b>   | <b>204927</b> | <b>423818</b> |
| 4       | <b>Expenses</b>                                                                    |               |               |               |                 |               |               |
|         | a) Cost of materials consumed                                                      | 67191         | 71370         | 55656         | 138561          | 103205        | 215457        |
|         | b) Purchases of stock-in-trade                                                     | 2666          | 5150          | 3053          | 7816            | 6293          | 12288         |
|         | c) Changes in inventories of finished goods, stock-in-trade and work-in-progress   | 536           | (11765)       | 1555          | (11229)         | 3967          | 2104          |
|         | d) Employee benefits expense                                                       | 10019         | 9760          | 9512          | 19779           | 19173         | 37295         |
|         | e) Finance costs                                                                   | 1911          | 1430          | 1410          | 3341            | 2893          | 5662          |
|         | f) Depreciation and amortisation expenses                                          | 4043          | 4052          | 3853          | 8095            | 7676          | 16118         |
|         | g) Other expenses:                                                                 |               |               |               |                 |               |               |
|         | - Power and fuel expense                                                           | 11988         | 13618         | 11048         | 25606           | 21438         | 44321         |
|         | - Others                                                                           | 15745         | 15746         | 14476         | 31491           | 26394         | 55145         |
|         | <b>Total expenses</b>                                                              | <b>114099</b> | <b>109361</b> | <b>100563</b> | <b>223460</b>   | <b>191039</b> | <b>388390</b> |
| 5       | <b>Profit before exceptional items and tax (3-4)</b>                               | <b>9473</b>   | <b>16961</b>  | <b>5946</b>   | <b>26434</b>    | <b>13888</b>  | <b>35428</b>  |
| 6       | Exceptional items                                                                  | -             | -             | -             | -               | -             | (1222)        |
| 7       | <b>Profit before tax (5+6)</b>                                                     | <b>9473</b>   | <b>16961</b>  | <b>5946</b>   | <b>26434</b>    | <b>13888</b>  | <b>34206</b>  |
| 8       | <b>Tax expense</b>                                                                 |               |               |               |                 |               |               |
|         | - Current tax                                                                      | 2367          | 3959          | 1253          | 6326            | 2920          | 6627          |
|         | - Deferred tax charge                                                              | 66            | 380           | 290           | 446             | 664           | 782           |
| 9       | <b>Net profit for the period/year (7-8)</b>                                        | <b>7040</b>   | <b>12622</b>  | <b>4403</b>   | <b>19662</b>    | <b>10304</b>  | <b>26797</b>  |
| 10      | <b>Other comprehensive income (OCI)</b>                                            |               |               |               |                 |               |               |
|         | i) a) Items that will not be reclassified to profit or loss                        | (462)         | 5             | 117           | (457)           | 47            | 20            |
|         | b) Income tax relating to items that will not be reclassified to profit or loss    | 116           | (1)           | (30)          | 115             | (12)          | (5)           |
|         | ii) a) Items that will be reclassified to profit or loss                           | -             | -             | -             | -               | -             | -             |
|         | b) Income tax relating to items that will be reclassified to profit or loss        | -             | -             | -             | -               | -             | -             |
| 11      | <b>Total comprehensive income for the period/year (9+10)</b>                       | <b>6694</b>   | <b>12626</b>  | <b>4490</b>   | <b>19320</b>    | <b>10339</b>  | <b>26812</b>  |
| 12      | <b>Earnings per share of ₹ 1 each (not annualised for the quarters/half years)</b> |               |               |               |                 |               |               |
|         | Basic (₹)                                                                          | 4.42          | 7.92          | 2.77          | 12.34           | 6.47          | 16.82         |
|         | Diluted (₹)                                                                        | 4.42          | 7.92          | 2.77          | 12.34           | 6.47          | 16.82         |
| 13      | Paid-up equity share capital (face value per share ₹ 1)                            | 1593          | 1593          | 1593          | 1593            | 1593          | 1593          |
| 14      | Reserves excluding revaluation reserves (other equity)                             |               |               |               | 278651          | 249354        | 262413        |
|         | See accompanying notes to the Standalone Unaudited Financial Results               |               |               |               |                 |               |               |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



# Jubilant Ingrevia Limited

## Statement of Standalone Unaudited Assets and Liabilities

(₹ in Lakhs)

| Sr. No.   | Particulars                                                                            | As at         | As at         |
|-----------|----------------------------------------------------------------------------------------|---------------|---------------|
|           |                                                                                        | 30 September  | 31 March      |
|           |                                                                                        | (Unaudited)   | (Audited)     |
|           |                                                                                        | 2026          | 2026          |
| <b>A</b>  | <b>ASSETS</b>                                                                          |               |               |
| <b>1.</b> | <b>Non-current assets</b>                                                              |               |               |
|           | Property, plant and equipment                                                          | 226197        | 229352        |
|           | Capital work-in-progress                                                               | 26804         | 13860         |
|           | Intangible assets                                                                      | 1377          | 1528          |
|           | Right of use assets                                                                    | 5833          | 5770          |
|           | <b>Financial assets</b>                                                                |               |               |
|           | Investments in subsidiaries and associates                                             | 32668         | 32657         |
|           | Loans                                                                                  | 10046         | 4136          |
|           | Other financial assets                                                                 | 976           | 951           |
|           | Income-tax assets (net)                                                                | 408           | 1207          |
|           | Other non-current assets                                                               | 1606          | 1963          |
|           | <b>Total non-current assets</b>                                                        | <b>305915</b> | <b>291424</b> |
| <b>2.</b> | <b>Current assets</b>                                                                  |               |               |
|           | Inventories                                                                            | 91406         | 73256         |
|           | <b>Financial assets</b>                                                                |               |               |
|           | Trade receivables                                                                      | 78460         | 68879         |
|           | Cash and cash equivalents                                                              | 13847         | 16467         |
|           | Other bank balances                                                                    | 150           | 134           |
|           | Loans                                                                                  | 20            | 32            |
|           | Other financial assets                                                                 | 8464          | 7579          |
|           | Other current assets                                                                   | 19677         | 14559         |
|           | <b>Total current assets</b>                                                            | <b>212024</b> | <b>180906</b> |
|           | <b>Total assets</b>                                                                    | <b>517939</b> | <b>472330</b> |
| <b>B</b>  | <b>EQUITY AND LIABILITIES</b>                                                          |               |               |
| <b>1.</b> | <b>Equity</b>                                                                          |               |               |
|           | Equity share capital                                                                   | 1593          | 1593          |
|           | Other equity                                                                           | 278651        | 262413        |
|           | <b>Total equity</b>                                                                    | <b>280244</b> | <b>264006</b> |
| <b>2.</b> | <b>Liabilities</b>                                                                     |               |               |
|           | <b>Non-current liabilities</b>                                                         |               |               |
|           | <b>Financial liabilities</b>                                                           |               |               |
|           | Borrowings                                                                             | 16343         | 22536         |
|           | Lease liabilities                                                                      | 3457          | 3540          |
|           | Provisions                                                                             | 7521          | 6710          |
|           | Deferred tax liabilities (net)                                                         | 23100         | 22768         |
|           | <b>Total non-current liabilities</b>                                                   | <b>50421</b>  | <b>55554</b>  |
|           | <b>Current liabilities</b>                                                             |               |               |
|           | <b>Financial liabilities</b>                                                           |               |               |
|           | Borrowings                                                                             | 62607         | 47934         |
|           | Lease liabilities                                                                      | 726           | 644           |
|           | Trade payables                                                                         |               |               |
|           | Total outstanding dues of micro enterprises and small enterprises                      | 8180          | 4289          |
|           | Total outstanding dues of creditors other than micro enterprises and small enterprises | 95299         | 83335         |
|           | Other financial liabilities                                                            | 12565         | 7311          |
|           | Other current liabilities                                                              | 3495          | 6065          |
|           | Provisions                                                                             | 1837          | 2185          |
|           | Current tax liabilities (net)                                                          | 2565          | 1007          |
|           | <b>Total current liabilities</b>                                                       | <b>187274</b> | <b>152770</b> |
|           | <b>Total equity and liabilities</b>                                                    | <b>517939</b> | <b>472330</b> |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



**Jubilant Ingrevia Limited**  
**Note1: Statement of Standalone Unaudited Cash Flows**

(₹ in Lakhs)

| Particulars                                                                                                                                  | Half Year Ended |               |
|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------|
|                                                                                                                                              | 30 September    | 30 September  |
|                                                                                                                                              | (Unaudited)     | (Unaudited)   |
|                                                                                                                                              | 2026            | 2025          |
| <b>A. Cash flows from operating activities</b>                                                                                               |                 |               |
| Profit before tax                                                                                                                            | 26434           | 13888         |
| Adjustments:                                                                                                                                 |                 |               |
| Depreciation and amortisation expenses                                                                                                       | 8095            | 7676          |
| Loss/(gain) on sale/disposal, discard of property, plant and equipment and assets written off (net)                                          | 418             | (48)          |
| Finance costs                                                                                                                                | 3341            | 2893          |
| Share-based payment expense                                                                                                                  | 900             | 503           |
| Unrealised foreign exchange (gain)/loss (net)                                                                                                | (165)           | 375           |
| Interest income                                                                                                                              | (343)           | (133)         |
| Allowance for expected credit loss on trade receivables                                                                                      | 27              | 20            |
|                                                                                                                                              | <b>12273</b>    | <b>11286</b>  |
| <b>Operating cash flows before working capital changes</b>                                                                                   | <b>38707</b>    | <b>25174</b>  |
| (Increase)/decrease in loans, other financial and non-financial assets                                                                       | (5829)          | 1275          |
| Increase in trade receivables                                                                                                                | (9424)          | (12104)       |
| Increase in inventories                                                                                                                      | (18150)         | (723)         |
| (Decrease)/increase in other financial liabilities, other current liabilities and provisions                                                 | (2746)          | 1623          |
| Increase in trade payables                                                                                                                   | 15837           | 1126          |
| <b>Cash generated from operations</b>                                                                                                        | <b>18395</b>    | <b>16371</b>  |
| Income tax paid (net of refund)                                                                                                              | (3969)          | (5502)        |
| <b>Net cash generated from operating activities</b>                                                                                          | <b>14426</b>    | <b>10869</b>  |
| <b>B. Cash flows from investing activities</b>                                                                                               |                 |               |
| Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital creditors and capital advances) | (11264)         | (6453)        |
| Proceeds from sale of property, plant and equipment                                                                                          | 188             | 313           |
| Loan given to subsidiaries                                                                                                                   | (2913)          | -             |
| Investment in an associate                                                                                                                   | -               | (205)         |
| Loan given to body corporate                                                                                                                 | (3000)          | -             |
| Movement in other bank balances (net)                                                                                                        | (33)            | (28)          |
| Interest received                                                                                                                            | 325             | 98            |
| <b>Net cash used in investing activities</b>                                                                                                 | <b>(16697)</b>  | <b>(6275)</b> |
| <b>C. Cash flows from financing activities</b>                                                                                               |                 |               |
| Repayment of non-current borrowings                                                                                                          | (4843)          | (3583)        |
| Repayment of non-current borrowings to subsidiary                                                                                            | (1500)          | -             |
| Proceeds from current borrowings (net)                                                                                                       | 14823           | 3255          |
| Payment of principal portion of lease liabilities                                                                                            | (435)           | (188)         |
| Dividend paid                                                                                                                                | (3966)          | (3954)        |
| Finance costs paid (including interest on lease liabilities)                                                                                 | (4428)          | (3599)        |
| <b>Net cash used in financing activities</b>                                                                                                 | <b>(349)</b>    | <b>(8069)</b> |
| <b>Net decrease in cash and cash equivalents (A+B+C)</b>                                                                                     | <b>(2620)</b>   | <b>(3475)</b> |
| Add: cash and cash equivalents at the beginning of the period                                                                                | 16467           | 4107          |
| <b>Cash and cash equivalents at the end of the period</b>                                                                                    | <b>13847</b>    | <b>632</b>    |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



# Jubilant Ingrevia Limited

Note 2: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year Ended 30 September 2026

(₹ in Lakhs)

| Sr. No. | Particulars                                                 | Quarter Ended |               |               | Half Year Ended |               | Year Ended    |
|---------|-------------------------------------------------------------|---------------|---------------|---------------|-----------------|---------------|---------------|
|         |                                                             | 30 September  | 30 June       | 30 September  | 30 September    | 30 September  | 31 March      |
|         |                                                             | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Unaudited)     | (Unaudited)   | (Audited)     |
|         |                                                             | 2026          | 2026          | 2025          | 2026            | 2025          | 2026          |
| 1       | <b>Segment revenue</b>                                      |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 59474         | 56853         | 52685         | 116327          | 103748        | 213992        |
|         | b. Nutrition & Health Solutions                             | 26871         | 22457         | 16525         | 49328           | 32926         | 72261         |
|         | c. Chemical Intermediates                                   | 48532         | 56527         | 41445         | 105059          | 77243         | 156053        |
|         | <b>Total</b>                                                | <b>134877</b> | <b>135837</b> | <b>110655</b> | <b>270714</b>   | <b>213917</b> | <b>442306</b> |
|         | Less : Inter segment revenue                                | 12282         | 10572         | 5237          | 22854           | 11191         | 28457         |
|         | <b>Total revenue from operations</b>                        | <b>122595</b> | <b>125265</b> | <b>105418</b> | <b>247860</b>   | <b>202726</b> | <b>413849</b> |
|         | a. Speciality Chemicals                                     | 47401         | 46428         | 47613         | 93829           | 92810         | 186216        |
|         | b. Nutrition & Health Solutions                             | 26831         | 22421         | 16518         | 49252           | 32901         | 72191         |
|         | c. Chemical Intermediates                                   | 48363         | 56416         | 41287         | 104779          | 77015         | 155442        |
|         | <b>Total</b>                                                | <b>122595</b> | <b>125265</b> | <b>105418</b> | <b>247860</b>   | <b>202726</b> | <b>413849</b> |
| 2       | <b>Segment results (profit before tax and interest)</b>     |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 9985          | 10169         | 9588          | 20154           | 20330         | 47789         |
|         | b. Nutrition & Health Solutions                             | 2192          | 1965          | 1145          | 4157            | 1502          | 3037          |
|         | c. Chemical Intermediates                                   | 1338          | 8452          | (1404)        | 9790            | (1215)        | (2173)        |
|         | <b>Total</b>                                                | <b>13515</b>  | <b>20586</b>  | <b>9329</b>   | <b>34101</b>    | <b>20617</b>  | <b>48653</b>  |
|         | Less: i. Interest (finance costs)                           | 1911          | 1430          | 1410          | 3341            | 2893          | 5662          |
|         | ii. Un-allocable expenditure (net of un-allocable income)   | 2131          | 2195          | 1973          | 4326            | 3836          | 7563          |
|         | iii. Exceptional Item - One Time impact of New Labour Codes | -             | -             | -             | -               | -             | 1222          |
|         | <b>Profit before tax</b>                                    | <b>9473</b>   | <b>16961</b>  | <b>5946</b>   | <b>26434</b>    | <b>13888</b>  | <b>34206</b>  |
| 3       | <b>Segment assets</b>                                       |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 260472        | 249260        | 238124        | 260472          | 238124        | 232316        |
|         | b. Nutrition & Health Solutions                             | 68408         | 71523         | 56353         | 68408           | 56353         | 61493         |
|         | c. Chemical Intermediates                                   | 138099        | 140850        | 128519        | 138099          | 128519        | 124896        |
|         | d. Unallocable corporate assets                             | 50960         | 55111         | 36790         | 50960           | 36790         | 53625         |
|         | <b>Total segment assets</b>                                 | <b>517939</b> | <b>516744</b> | <b>459786</b> | <b>517939</b>   | <b>459786</b> | <b>472330</b> |
| 4       | <b>Segment liabilities</b>                                  |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 59952         | 52471         | 40055         | 59952           | 40055         | 42659         |
|         | b. Nutrition & Health Solutions                             | 16286         | 15656         | 16230         | 16286           | 16230         | 15300         |
|         | c. Chemical Intermediates                                   | 55960         | 59931         | 51324         | 55960           | 51324         | 55025         |
|         | d. Unallocable corporate liabilities                        | 105497        | 111619        | 101230        | 105497          | 101230        | 95340         |
|         | <b>Total segment liabilities</b>                            | <b>237695</b> | <b>239677</b> | <b>208839</b> | <b>237695</b>   | <b>208839</b> | <b>208324</b> |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



# Jubilant Ingrevia Limited

Note 3: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Standalone)

| Sr. No. | Particulars                                                                                                                                                                                                                                                                                                                                                                                             | Quarter Ended                       |                                |                                     | Half Year Ended                     |                                     | Year Ended<br>31 March<br>(Audited) |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|         |                                                                                                                                                                                                                                                                                                                                                                                                         | 30 September<br>(Unaudited)<br>2026 | 30 June<br>(Unaudited)<br>2026 | 30 September<br>(Unaudited)<br>2025 | 30 September<br>(Unaudited)<br>2026 | 30 September<br>(Unaudited)<br>2025 |                                     |
|         |                                                                                                                                                                                                                                                                                                                                                                                                         |                                     |                                |                                     |                                     |                                     |                                     |
| 1       | Debt service coverage ratio (in times)#<br>Definition: EBITDA/finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)<br>(EBITDA: Profit before tax + depreciation and amortisation expense + finance costs)                                                                                                                                      | 3.56                                | 5.83                           | 3.50                                | 4.63                                | 3.78                                | 4.13                                |
| 2       | Interest service coverage ratio (in times)<br>Definition: EBITDA/finance costs                                                                                                                                                                                                                                                                                                                          | 8.07                                | 15.69                          | 7.95                                | 11.34                               | 8.45                                | 10.10                               |
| 3       | Bad debts to account receivable ratio (%)#<br>Definition: Bad debts/average of opening and closing trade receivables<br>(Bad debts: Impairment balance as per statements of profit and loss)                                                                                                                                                                                                            | 0.01%                               | 0.03%                          | 0.03%                               | 0.04%                               | 0.03%                               | 0.12%                               |
| 4       | Debtors turnover (in times)#<br>Definition: Revenue from operations/average of opening and closing trade receivables                                                                                                                                                                                                                                                                                    | 1.53                                | 1.67                           | 1.59                                | 3.36                                | 3.20                                | 6.56                                |
| 5       | Inventory turnover (in times)#<br>Definition: Cost of goods sold/average of opening and closing inventories                                                                                                                                                                                                                                                                                             | 0.77                                | 0.79                           | 0.71                                | 1.64                                | 1.40                                | 2.99                                |
| 6       | Operating margin (%)<br>Definition: Operating profit/revenue from operations<br>(Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses)<br>(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress) | 8.49%                               | 13.84%                         | 5.94%                               | 11.19%                              | 7.19%                               | 7.52%                               |
| 7       | Net profit margin (%)<br>Definition: Net profit/total income                                                                                                                                                                                                                                                                                                                                            | 5.70%                               | 9.99%                          | 4.13%                               | 7.87%                               | 5.03%                               | 6.32%                               |
| 8       | Net worth (in ₹ Lakhs)<br>(Net worth: Equity share capital + other equity)                                                                                                                                                                                                                                                                                                                              | 280244                              | 277067                         | 250947                              | 280244                              | 250947                              | 264006                              |
| 9       | Debt equity ratio (in times)<br>Definition: Net debts/net worth<br>(Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances)                                                                                                                                                                                             | 0.23                                | 0.23                           | 0.31                                | 0.23                                | 0.31                                | 0.20                                |
| 10      | Current ratio (in times)<br>Definition: Current assets/current liabilities                                                                                                                                                                                                                                                                                                                              | 1.13                                | 1.17                           | 1.19                                | 1.13                                | 1.19                                | 1.18                                |
| 11      | Long term debt to working capital (in times)<br>Definition: Long term debt/working capital<br>(Long term debt: Long term borrowings (gross of transaction costs)<br>(working capital: Current assets - current liabilities)                                                                                                                                                                             | 0.66                                | 0.60                           | 1.10                                | 0.66                                | 1.10                                | 0.80                                |
| 12      | Current liability ratio (in times)<br>Definition: Current liabilities/total liabilities                                                                                                                                                                                                                                                                                                                 | 0.79                                | 0.78                           | 0.70                                | 0.79                                | 0.70                                | 0.73                                |
| 13      | Total debts to total assets (in times)<br>Definition: Total debts/total assets<br>(Total debts: Long term borrowings (gross of transaction costs) + short term borrowings)                                                                                                                                                                                                                              | 0.15                                | 0.16                           | 0.17                                | 0.15                                | 0.17                                | 0.15                                |

# not annualised for the quarters and half years



SIGNED FOR  
IDENTIFICATION  
PURPOSES



**Notes to standalone unaudited financial results (cont'd):**

4. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI Circular SEBI/HO/DDHS/DDHS PoD/P/CIR/2025/0000000137 dated 15 October 2025.
5. During the quarter, the Company has entered into a Binding Term Sheet with Zettaone Technologies India Private Limited ('Zettaone') to acquire a 40% strategic equity stake for an aggregate consideration of approximately ₹ 18920 lakhs. For the proposed acquisition, the Company has incorporated Jubilant Advanced Electronics Limited, a wholly owned subsidiary, on 12 October 2026. The investment is aligned with the Company's Pinnacle growth strategy and is expected to strengthen its presence in the Electronics Development and Manufacturing Services (EDMS) space, enabling an integrated offering across the electronics and semiconductor ecosystem and supporting long-term sustainable growth.
6. As on 30 September 2026, the Company has outstanding unsecured listed commercial papers ('CPs') of ₹ 10000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:
- | ISIN No.     | Issue date        | Due date of repayment | Redemption amount |
|--------------|-------------------|-----------------------|-------------------|
| INE0BY014433 | 24 September 2026 | 23 December 2026      | ₹ 10000 lakhs     |
7. During the quarter ended 30 September 2026, the Company has granted 42298 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company and allotted 41989 equity shares on exercise of vested stock options by eligible employees.
8. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Company has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of ₹ 1222 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the previous quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Company is currently evaluating the consequential impact of these Rules. The Company continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.
9. During the quarter, the Company has paid a final dividend of ₹ 2.5 per equity share of (₹ 1 each) amounting to ₹ 3982 lakhs for the year ended 31 March 2026 post shareholders' approval at the Annual General Meeting held on 26 August 2026.
10. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27 October 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at [www.jubilantingrevia.com](http://www.jubilantingrevia.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

Place : Noida

Date : 27 October 2026

For Jubilant Ingrevia Limited



Deepak Jain

CEO &amp; Managing Director

**SIGNED FOR  
IDENTIFICATION  
PURPOSES**

**Walker Chandiok & Co LLP**

21<sup>st</sup> Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram- 122002  
India

T +91 120 485 5999  
F +91 120 485 5902

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Jubilant Ingrevia Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025.
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

## Walker Chandiok & Co LLP

### Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 Regulation 52(4) of the Listing Regulations read with SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated 15 October 2025, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement also includes the Group's share of net loss after tax of ₹ 3 lakhs and ₹ 6 lakhs, and total comprehensive loss of ₹ 3 lakhs and ₹ 6 lakhs for the quarter and year-to-date period ended on 30 September 2026 respectively, in respect of an associate, based on their interim financial information, which have not been reviewed by their auditor and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the said associate, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.

#### For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

*Madhu Sudan*



**Madhu Sudan Malpani**

Partner

Membership No. 517440

UDIN: 26517440YDZZWI3770

**Place:** Noida

**Date:** 27 October 2026

## Walker ChandioK & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

### Annexure 1

#### List of entities included in the Statement

| S. No | Name                                                                                                               | Relationship with the Holding Company       |
|-------|--------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| 1     | Jubilant Infrastructure Limited                                                                                    | Subsidiary                                  |
| 2     | Jubilant Agro Science Limited                                                                                      | Subsidiary                                  |
| 3     | Jubilant Ingrevia (USA) Inc. (formally known as Jubilant Life Science (USA) Inc.)                                  | Subsidiary                                  |
| 4     | Jubilant Life Sciences NV                                                                                          | Subsidiary                                  |
| 5     | Jubilant Ingrevia International Pte. Limited (formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary                                  |
| 6     | Jubilant Life Sciences (Shanghai) Limited                                                                          | Subsidiary                                  |
| 7     | Jubilant Ingrevia Employee Welfare Trust                                                                           | Subsidiary                                  |
| 8     | Remidex Pharma Private Limited                                                                                     | Subsidiary (with effect from 30 March 2026) |
| 9     | Mister Veg Foods Private Limited                                                                                   | Associate                                   |
| 10    | AMP Energy Green Fifteen Private Limited                                                                           | Associate                                   |
| 11    | O2 Renewable Energy XVIII Private Limited                                                                          | Associate (with effect from 25 April 2025)  |



**Jubilant Ingrevia Limited**

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubil.com, Tel: +91-5924-267437

**Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30 September 2026**

| Sr. No. | Particulars                                                                        | Quarter Ended |               |               |               |               |               | Year Ended |
|---------|------------------------------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|------------|
|         |                                                                                    | 30 September  | 30 June       | 30 September  | 30 September  | 30 September  | 31 March      |            |
|         |                                                                                    | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Audited)     |            |
|         |                                                                                    | 2026          | 2026          | 2025          | 2026          | 2025          | 2026          |            |
| 1       | <b>Revenue from operations</b>                                                     |               |               |               |               |               |               |            |
|         | a) Sales/Income from operations                                                    | 138115        | 128873        | 110966        | 266988        | 213908        | 434485        |            |
|         | b) Other operating income                                                          | 1308          | 1154          | 1107          | 2462          | 1960          | 4322          |            |
|         | <b>Total revenue from operations</b>                                               | <b>139423</b> | <b>130027</b> | <b>112073</b> | <b>269450</b> | <b>215868</b> | <b>438807</b> |            |
| 2       | Other income                                                                       | 903           | 1022          | 1081          | 1925          | 2203          | 4053          |            |
| 3       | <b>Total income (1+2)</b>                                                          | <b>140326</b> | <b>131049</b> | <b>113154</b> | <b>271375</b> | <b>218071</b> | <b>442860</b> |            |
| 4       | <b>Expenses</b>                                                                    |               |               |               |               |               |               |            |
|         | a) Cost of materials consumed                                                      | 69790         | 71768         | 54795         | 141558        | 99686         | 210462        |            |
|         | b) Purchases of stock-in-trade                                                     | 2290          | 6405          | 3060          | 8695          | 6300          | 14904         |            |
|         | c) Changes in inventories of finished goods, stock-in-trade and work-in progress   | 81            | (15316)       | 2196          | (15235)       | 6009          | 4111          |            |
|         | d) Employee benefits expense                                                       | 12211         | 11736         | 10750         | 23947         | 21573         | 42561         |            |
|         | e) Finance costs                                                                   | 2250          | 1743          | 1216          | 3993          | 2485          | 4912          |            |
|         | f) Depreciation and amortisation expenses                                          | 5093          | 5101          | 4123          | 10194         | 8207          | 17548         |            |
|         | g) Other expenses:                                                                 |               |               |               |               |               |               |            |
|         | - Power and fuel expense                                                           | 12300         | 13846         | 10663         | 26146         | 20659         | 41783         |            |
|         | - Others                                                                           | 21510         | 21677         | 17057         | 43187         | 33875         | 68282         |            |
|         | <b>Total expenses</b>                                                              | <b>125525</b> | <b>116960</b> | <b>103860</b> | <b>242485</b> | <b>198794</b> | <b>404563</b> |            |
| 5       | <b>Profit before share of profit/(loss) of an associate (3-4)</b>                  | <b>14801</b>  | <b>14089</b>  | <b>9294</b>   | <b>28890</b>  | <b>19277</b>  | <b>38297</b>  |            |
| 6       | Share of loss of an associate                                                      | (3)           | (3)           | (8)           | (6)           | (14)          | (18)          |            |
| 7       | <b>Profit before exceptional items and tax (5+6)</b>                               | <b>14798</b>  | <b>14086</b>  | <b>9286</b>   | <b>28884</b>  | <b>19263</b>  | <b>38279</b>  |            |
| 8       | Exceptional items                                                                  | -             | -             | -             | -             | -             | (1304)        |            |
| 9       | <b>Profit before tax (7+8)</b>                                                     | <b>14798</b>  | <b>14086</b>  | <b>9286</b>   | <b>28884</b>  | <b>19263</b>  | <b>36975</b>  |            |
| 10      | <b>Tax expense</b>                                                                 |               |               |               |               |               |               |            |
|         | - Current tax                                                                      | 2312          | 4296          | 1534          | 6608          | 3851          | 8423          |            |
|         | - Deferred tax charge/(credit)                                                     | 1343          | (792)         | 805           | 551           | 955           | 761           |            |
| 11      | <b>Net profit for the period/year (9-10)</b>                                       | <b>11143</b>  | <b>10582</b>  | <b>6947</b>   | <b>21725</b>  | <b>14457</b>  | <b>27791</b>  |            |
| 12      | <b>Other comprehensive income (OCI)</b>                                            |               |               |               |               |               |               |            |
|         | i) a) Items that will not be reclassified to profit or loss                        | (449)         | 274           | 435           | (175)         | 595           | 87            |            |
|         | b) Income tax relating to items that will not be reclassified to profit or loss    | 115           | (41)          | (37)          | 74            | (53)          | (13)          |            |
|         | ii) a) Items that will be reclassified to profit or loss                           | 80            | 176           | 440           | 256           | 1619          | 2617          |            |
|         | b) Income tax relating to items that will be reclassified to profit or loss        | 84            | 97            | (92)          | 181           | (408)         | (659)         |            |
| 13      | <b>Total comprehensive income for the period/year (11+12)</b>                      | <b>10973</b>  | <b>11088</b>  | <b>7693</b>   | <b>22061</b>  | <b>16210</b>  | <b>29823</b>  |            |
|         | <b>Net profit attributable to:</b>                                                 |               |               |               |               |               |               |            |
|         | Owners of the Company                                                              | 11143         | 10582         | 6947          | 21725         | 14457         | 27791         |            |
|         | Non-controlling interests                                                          | -             | -             | -             | -             | -             | -             |            |
|         | <b>Other comprehensive income attributable to:</b>                                 |               |               |               |               |               |               |            |
|         | Owners of the Company                                                              | (170)         | 506           | 746           | 336           | 1753          | 2032          |            |
|         | Non-controlling interests                                                          | -             | -             | -             | -             | -             | -             |            |
|         | <b>Total comprehensive income attributable to:</b>                                 |               |               |               |               |               |               |            |
|         | Owners of the Company                                                              | 10973         | 11088         | 7693          | 22061         | 16210         | 29823         |            |
|         | Non-controlling interests                                                          | -             | -             | -             | -             | -             | -             |            |
| 14      | <b>Earnings per share of ₹ 1 each (not annualised for the quarters/half years)</b> |               |               |               |               |               |               |            |
|         | Basic (₹)                                                                          | 7.07          | 6.70          | 4.40          | 13.77         | 9.15          | 17.59         |            |
|         | Diluted (₹)                                                                        | 7.06          | 6.68          | 4.40          | 13.74         | 9.15          | 17.51         |            |
| 15      | <b>Paid-up equity share capital (face value per share ₹ 1)</b>                     | <b>1578</b>   | <b>1577</b>   | <b>1580</b>   | <b>1578</b>   | <b>1580</b>   | <b>1577</b>   |            |
| 16      | <b>Reserves excluding revaluation reserves (other equity)</b>                      |               |               |               | 330062        | 302505        | 311045        |            |
|         | <b>See accompanying notes to the Consolidated Unaudited Financial Results</b>      |               |               |               |               |               |               |            |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**




# Jubilant Ingrevia Limited

## Statement of Consolidated Unaudited Assets and Liabilities

(₹ in Lakhs)

| Sr. No.   | Particulars                                                                            | As at         | As at         |
|-----------|----------------------------------------------------------------------------------------|---------------|---------------|
|           |                                                                                        | 30 September  | 31 March      |
|           |                                                                                        | (Unaudited)   | (Audited)     |
|           |                                                                                        | 2026          | 2026          |
| <b>A</b>  | <b>ASSETS</b>                                                                          |               |               |
| <b>1.</b> | <b>Non-current assets</b>                                                              |               |               |
|           | Property, plant and equipment                                                          | 307891        | 310362        |
|           | Capital work-in-progress                                                               | 28057         | 15394         |
|           | Goodwill                                                                               | 613           | 613           |
|           | Other Intangible assets                                                                | 2718          | 2889          |
|           | Right of use assets                                                                    | 4461          | 4479          |
|           | Investments accounted for using the equity method                                      | 685           | 677           |
|           | <b>Financial assets</b>                                                                |               |               |
|           | Investments                                                                            | 3035          | 2639          |
|           | Loans                                                                                  | 34            | 38            |
|           | Other financial assets                                                                 | 4145          | 1267          |
|           | Deferred tax assets (net)                                                              | 1374          | 1420          |
|           | Income-tax assets (net)                                                                | 821           | 1387          |
|           | Other non-current assets                                                               | 2109          | 2570          |
|           | <b>Total non-current assets</b>                                                        | <b>355943</b> | <b>343735</b> |
| <b>2.</b> | <b>Current assets</b>                                                                  |               |               |
|           | Inventories                                                                            | 108365        | 87996         |
|           | <b>Financial assets</b>                                                                |               |               |
|           | Trade receivables                                                                      | 90803         | 78254         |
|           | Cash and cash equivalents                                                              | 20069         | 18847         |
|           | Other bank balances                                                                    | 150           | 146           |
|           | Loans                                                                                  | 33            | 43            |
|           | Other financial assets                                                                 | 3950          | 4509          |
|           | Other current assets                                                                   | 20590         | 14843         |
|           | <b>Total current assets</b>                                                            | <b>243960</b> | <b>204638</b> |
|           | <b>Total assets</b>                                                                    | <b>599903</b> | <b>548373</b> |
| <b>B</b>  | <b>EQUITY AND LIABILITIES</b>                                                          |               |               |
| <b>1.</b> | <b>Equity</b>                                                                          |               |               |
|           | Equity share capital                                                                   | 1578          | 1577          |
|           | Other equity                                                                           | 330062        | 311045        |
|           | <b>Total equity attributable to equity shareholders</b>                                | <b>331640</b> | <b>312622</b> |
| <b>2.</b> | <b>Liabilities</b>                                                                     |               |               |
|           | <b>Non-current liabilities</b>                                                         |               |               |
|           | <b>Financial liabilities</b>                                                           |               |               |
|           | Borrowings                                                                             | 24592         | 32211         |
|           | Lease liabilities                                                                      | 677           | 763           |
|           | Other financial liabilities                                                            | 12638         | 12126         |
|           | Provisions                                                                             | 8131          | 7281          |
|           | Deferred tax liabilities (net)                                                         | 24451         | 24199         |
|           | <b>Total non-current liabilities</b>                                                   | <b>70489</b>  | <b>76580</b>  |
|           | <b>Current liabilities</b>                                                             |               |               |
|           | <b>Financial liabilities</b>                                                           |               |               |
|           | Borrowings                                                                             | 63882         | 45888         |
|           | Lease liabilities                                                                      | 379           | 319           |
|           | Trade payables                                                                         |               |               |
|           | Total outstanding dues of micro enterprises and small enterprises                      | 8973          | 4861          |
|           | Total outstanding dues of creditors other than micro enterprises and small enterprises | 100748        | 89204         |
|           | Other financial liabilities                                                            | 15919         | 12960         |
|           | Other current liabilities                                                              | 2740          | 2354          |
|           | Provisions                                                                             | 2472          | 2305          |
|           | Current tax liabilities (net)                                                          | 2661          | 1280          |
|           | <b>Total current liabilities</b>                                                       | <b>197774</b> | <b>159171</b> |
|           | <b>Total equity and liabilities</b>                                                    | <b>599903</b> | <b>548373</b> |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



**Jubilant Ingrevia Limited**  
**Note1: Statement of Consolidated Unaudited Cash Flows**

(₹ in Lakhs)

| Particulars                                                                                                                                  | Half Year Ended |               |
|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------|
|                                                                                                                                              | 30 September    | 30 September  |
|                                                                                                                                              | (Unaudited)     | (Unaudited)   |
|                                                                                                                                              | 2026            | 2025          |
| <b>A. Cash flows from operating activities</b>                                                                                               |                 |               |
| Profit before tax                                                                                                                            | 28884           | 19263         |
| Adjustments:                                                                                                                                 |                 |               |
| Depreciation and amortisation expenses                                                                                                       | 10194           | 8207          |
| Loss/(gain) on sale/disposal, discard of property, plant and equipment and assets written off (net)                                          | 445             | (51)          |
| Finance costs                                                                                                                                | 3993            | 2485          |
| Share-based payment expense                                                                                                                  | 900             | 503           |
| Unrealised foreign exchange (gain)/ loss (net)                                                                                               | (167)           | 375           |
| Interest income                                                                                                                              | (105)           | (110)         |
| Share of loss of an associate                                                                                                                | 6               | 14            |
| Allowance for expected credit loss on trade receivables                                                                                      | 30              | 20            |
|                                                                                                                                              | 15296           | 11443         |
| <b>Operating cash flows before working capital changes</b>                                                                                   | <b>44180</b>    | <b>30706</b>  |
| Increase in loans, other financial and non-financial assets                                                                                  | (4842)          | (1768)        |
| Increase in trade receivables                                                                                                                | (12395)         | (14962)       |
| (Increase)/decrease in inventories                                                                                                           | (20369)         | 1561          |
| Increase in other financial liabilities, other current liabilities and provisions                                                            | 584             | 362           |
| Increase/(decrease) in trade payables                                                                                                        | 15640           | (77)          |
| <b>Cash generated from operations</b>                                                                                                        | <b>22798</b>    | <b>15822</b>  |
| Income tax paid (net of refund)                                                                                                              | (4663)          | (6114)        |
| <b>Net cash generated from operating activities</b>                                                                                          | <b>18135</b>    | <b>9708</b>   |
| <b>B. Cash flows from investing activities</b>                                                                                               |                 |               |
| Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital creditors and capital advances) | (16098)         | (13367)       |
| Proceeds from sale of property, plant and equipment                                                                                          | 307             | 313           |
| Investment in an associate                                                                                                                   | -               | (205)         |
| Investment in equity instruments                                                                                                             | (117)           | -             |
| Movement in current investments (net)                                                                                                        | -               | 1621          |
| Loan given to body corporate                                                                                                                 | (3000)          | -             |
| Movement in other bank balances (net)                                                                                                        | (21)            | 1931          |
| Interest received                                                                                                                            | 79              | 82            |
| <b>Net cash used in investing activities</b>                                                                                                 | <b>(18850)</b>  | <b>(9625)</b> |
| <b>C. Cash flows from financing activities</b>                                                                                               |                 |               |
| Acquisition of treasury shares by Jubilant Ingrevia Employee Welfare Trust                                                                   | -               | (1447)        |
| Proceeds from sale of equity shares by Jubilant Ingrevia Employee Welfare Trust on exercise of stock options#                                | 0               | 60            |
| Proceeds from non-current borrowings                                                                                                         | -               | 4500          |
| Repayment of non-current borrowings                                                                                                          | (5218)          | (3958)        |
| Proceeds from current borrowings (net)                                                                                                       | 15594           | 3255          |
| Payment of principal portion of lease liabilities                                                                                            | (209)           | (163)         |
| Dividend paid                                                                                                                                | (3927)          | (3922)        |
| Finance costs paid (including interest on lease liabilities)                                                                                 | (4559)          | (3279)        |
| <b>Net cash generated/(used) in financing activities</b>                                                                                     | <b>1681</b>     | <b>(4954)</b> |
| <b>D. Effect of exchange rate changes</b>                                                                                                    | <b>256</b>      | <b>1619</b>   |
| <b>Net Increase/(decrease) in cash and cash equivalents (A+B+C+D)</b>                                                                        | <b>1222</b>     | <b>(3252)</b> |
| Add: cash and cash equivalents at the beginning of the period                                                                                | 18847           | 6936          |
| <b>Cash and cash equivalents at the end of the period</b>                                                                                    | <b>20069</b>    | <b>3684</b>   |

# Rounded Off



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



| Sr. No. | Particulars                                                 | Quarter Ended |               |               | Half Year Ended |               | Year Ended    |
|---------|-------------------------------------------------------------|---------------|---------------|---------------|-----------------|---------------|---------------|
|         |                                                             | 30 September  | 30 June       | 30 September  | 30 September    | 30 September  | 31 March      |
|         |                                                             | (Unaudited)   | (Unaudited)   | (Unaudited)   | (Unaudited)     | (Unaudited)   | (Audited)     |
|         |                                                             | 2026          | 2026          | 2025          | 2026            | 2025          | 2026          |
| 1       | Segment revenue                                             |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 68116         | 63700         | 53544         | 131816          | 107241        | 221426        |
|         | b. Nutrition & Health Solutions                             | 27070         | 24382         | 18061         | 51452           | 35948         | 79040         |
|         | c. Chemical Intermediates                                   | 56519         | 52517         | 45705         | 109036          | 83870         | 166798        |
|         | <b>Total</b>                                                | <b>151705</b> | <b>140599</b> | <b>117310</b> | <b>292304</b>   | <b>227059</b> | <b>467264</b> |
|         | Less : Inter segment revenue                                | 12282         | 10572         | 5237          | 22854           | 11191         | 28457         |
|         | <b>Total revenue from operations</b>                        | <b>139423</b> | <b>130027</b> | <b>112073</b> | <b>269450</b>   | <b>215868</b> | <b>438807</b> |
|         | a. Speciality Chemicals                                     | 56043         | 53274         | 48472         | 109317          | 96303         | 193650        |
|         | b. Nutrition & Health Solutions                             | 27031         | 24346         | 18054         | 51377           | 35923         | 78970         |
|         | c. Chemical Intermediates                                   | 56349         | 52407         | 45547         | 108756          | 83642         | 166187        |
|         | <b>Total</b>                                                | <b>139423</b> | <b>130027</b> | <b>112073</b> | <b>269450</b>   | <b>215868</b> | <b>438807</b> |
| 2       | Segment results (profit before tax and interest)            |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 11022         | 10914         | 10037         | 21936           | 20660         | 41038         |
|         | b. Nutrition & Health Solutions                             | 3134          | 2826          | 1662          | 5960            | 3661          | 7942          |
|         | c. Chemical Intermediates                                   | 5156          | 4397          | 795           | 9553            | 1292          | 1891          |
|         | <b>Total</b>                                                | <b>19312</b>  | <b>18137</b>  | <b>12494</b>  | <b>37449</b>    | <b>25613</b>  | <b>50871</b>  |
|         | Less: i. Interest (finance costs)                           | 2250          | 1743          | 1216          | 3993            | 2485          | 4912          |
|         | ii. Un-allocable expenditure (net of un-allocable income)   | 2264          | 2308          | 1992          | 4572            | 3865          | 7680          |
|         | iii. Exceptional Item - One Time Impact of New Labour Codes | -             | -             | -             | -               | -             | 1304          |
|         | <b>Profit before tax</b>                                    | <b>14798</b>  | <b>14086</b>  | <b>9286</b>   | <b>28884</b>    | <b>19263</b>  | <b>36975</b>  |
|         |                                                             |               |               |               |                 |               |               |
| 3       | Segment assets                                              |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 322235        | 317063        | 288850        | 322235          | 288850        | 295402        |
|         | b. Nutrition & Health Solutions                             | 86868         | 90131         | 78697         | 86868           | 78697         | 80308         |
|         | c. Chemical Intermediates                                   | 159382        | 157139        | 145152        | 159382          | 145152        | 143884        |
|         | d. Unallocable corporate assets                             | 31418         | 33298         | 12958         | 31418           | 12958         | 28779         |
|         | <b>Total segment assets</b>                                 | <b>599903</b> | <b>597631</b> | <b>525657</b> | <b>599903</b>   | <b>525657</b> | <b>548373</b> |
| 4       | Segment liabilities                                         |               |               |               |                 |               |               |
|         | a. Speciality Chemicals                                     | 90780         | 73622         | 56274         | 90780           | 56274         | 64627         |
|         | b. Nutrition & Health Solutions                             | 16460         | 16853         | 12596         | 16460           | 12596         | 14686         |
|         | c. Chemical Intermediates                                   | 55323         | 60535         | 48805         | 55323           | 48805         | 53017         |
|         | d. Unallocable corporate liabilities                        | 105700        | 122476        | 103897        | 105700          | 103897        | 103421        |
|         | <b>Total segment liabilities</b>                            | <b>268263</b> | <b>273486</b> | <b>221572</b> | <b>268263</b>   | <b>221572</b> | <b>235751</b> |



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**



# Jubilant Ingrevia Limited

Note 3: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Consolidated)

| Sr. No. | Particulars                                                                                                                                                                                                                                                                                     | Quarter Ended                       |                                |                                     | Half Year Ended                     |                                     | Year Ended<br>31 March<br>(Audited) |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|         |                                                                                                                                                                                                                                                                                                 | 30 September<br>(Unaudited)<br>2026 | 30 June<br>(Unaudited)<br>2026 | 30 September<br>(Unaudited)<br>2025 | 30 September<br>(Unaudited)<br>2026 | 30 September<br>(Unaudited)<br>2025 |                                     |
|         |                                                                                                                                                                                                                                                                                                 |                                     |                                |                                     |                                     |                                     |                                     |
| 1       | Debt service coverage ratio (in times)#<br>Definition: EBITDA/finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)<br>(EBITDA: Profit before tax + depreciation and amortisation expense + finance costs)                              | 4.56                                | 4.81                           | 4.58                                | 4.68                                | 4.65                                | 4.39                                |
| 2       | Interest service coverage ratio (in times)<br>Definition: EBITDA/finance costs                                                                                                                                                                                                                  | 9.84                                | 12.01                          | 12.02                               | 10.79                               | 12.05                               | 12.36                               |
| 3       | Bad debts to account receivable ratio (%)#<br>Definition: Bad debts/average of opening and closing trade receivables<br>(Bad debts: Impairment balance as per statements of profit and loss)                                                                                                    | 0.01%                               | 0.02%                          | 0.03%                               | 0.04%                               | 0.03%                               | 0.11%                               |
| 4       | Debtors turnover (in times)#<br>Definition: Revenue from operations/average of opening and closing trade receivables                                                                                                                                                                            | 1.52                                | 1.52                           | 1.55                                | 3.19                                | 3.16                                | 6.32                                |
| 5       | Inventory turnover (in times)#<br>Definition: Cost of goods sold/average of opening and closing inventories                                                                                                                                                                                     | 0.66                                | 0.64                           | 0.62                                | 1.38                                | 1.20                                | 2.52                                |
| 6       | Operating margin (%)<br>Definition: Operating profit/revenue from operations<br>(Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses)                                                           | 11.58%                              | 11.39%                         | 8.41%                               | 11.49%                              | 9.06%                               | 8.92%                               |
| 7       | Net profit margin (%)<br>Definition: Net profit/total income<br>(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress)                                                                  | 7.94%                               | 8.07%                          | 6.14%                               | 8.01%                               | 6.63%                               | 6.28%                               |
| 8       | Net worth (in ₹ Lakhs)<br>(Net worth: Equity share capital + other equity)                                                                                                                                                                                                                      | 331640                              | 324145                         | 304085                              | 331640                              | 304085                              | 312622                              |
| 9       | Debt equity ratio (in times)<br>Definition: Net debts/net worth<br>(Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances)                                                                                     | 0.21                                | 0.22                           | 0.25                                | 0.21                                | 0.25                                | 0.19                                |
| 10      | Current ratio (in times)<br>Definition: Current assets/current liabilities<br>Long term debt to working capital<br>Definition: Long term debt/working capital<br>(Long term debt: Long term borrowings (gross of transaction costs))<br>(working capital: Current assets - current liabilities) | 1.23                                | 1.24                           | 1.35                                | 1.23                                | 1.35                                | 1.29                                |
| 11      | Current liability ratio (in times)<br>Definition: Current liabilities/total liabilities<br>Total debts to total assets (in times)<br>Definition: Total debts/total assets<br>(Total debts: Long term borrowings (gross of transaction costs) + short term borrowings)                           | 0.53                                | 0.59                           | 0.71                                | 0.53                                | 0.71                                | 0.71                                |
| 12      |                                                                                                                                                                                                                                                                                                 | 0.74                                | 0.74                           | 0.65                                | 0.74                                | 0.65                                | 0.68                                |
| 13      |                                                                                                                                                                                                                                                                                                 | 0.15                                | 0.15                           | 0.15                                | 0.15                                | 0.15                                | 0.14                                |

# not annualised for the quarters and half years



SIGNED FOR  
IDENTIFICATION  
PURPOSES



**Notes to consolidated unaudited financial results (cont'd):**

4. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) read with SEBI Circular SEBI/HO/DDHS/DDHS PoD/P/CIR/2025/000000137 dated 15 October 2025.

5. The Group comprises of the following components:

| Name                                                                                                                  | Relationship with the Holding Company       |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Jubilant Infrastructure Limited                                                                                       | Subsidiary                                  |
| Jubilant Agro Science Limited                                                                                         | Subsidiary                                  |
| Jubilant Ingrevia (USA) Inc.<br>(formally known as Jubilant Life Science (USA) Inc.)                                  | Subsidiary                                  |
| Jubilant Life Sciences NV                                                                                             | Subsidiary                                  |
| Jubilant Ingrevia International Pte. Limited<br>(formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary                                  |
| Jubilant Life Sciences (Shanghai) Limited                                                                             | Subsidiary                                  |
| Jubilant Ingrevia Employee Welfare Trust                                                                              | Subsidiary                                  |
| Remidex Pharma Private Limited                                                                                        | Subsidiary (with effect from 30 March 2026) |
| Mister Veg Foods Private Limited                                                                                      | Associate                                   |
| AMP Energy Green Fifteen Private Limited                                                                              | Associate                                   |
| O2 Renewable Energy XVIII Private Limited                                                                             | Associate (with effect from 25 April 2025)  |

6. During the quarter, the Holding Company has entered into a Binding Term Sheet with Zettaone Technologies India Private Limited ('Zettaone') to acquire a 40% strategic equity stake for an aggregate consideration of approximately ₹ 18920 lakhs. For the proposed acquisition, the Holding Company has incorporated Jubilant Advanced Electronics Limited, a wholly owned subsidiary, on 12 October 2026. The investment is aligned with the Company's Pinnacle growth strategy and is expected to strengthen its presence in the Electronics Development and Manufacturing Services (EDMS) space, enabling an integrated offering across the electronics and semiconductor ecosystem and supporting long-term sustainable growth.

7. As on 30 September 2026, the Holding Company has outstanding unsecured listed commercial papers ('CPs') of ₹ 10000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

| ISIN No.     | Issue date        | Due date of repayment | Redemption amount |
|--------------|-------------------|-----------------------|-------------------|
| INEOBY014433 | 24 September 2026 | 23 December 2026      | ₹ 10000 lakhs     |

8. During the quarter ended 30 September 2026, the Holding Company has granted 42298 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company and allotted 41989 equity shares on exercise of vested stock options by eligible employees.
9. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Group has assessed the impact of these changes in accordance with Ind AS 19 - Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of ₹ 1304 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the previous quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Group is currently evaluating the consequential impact of these Rules. The Group continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.
10. During the quarter, the Holding Company has paid a final dividend of ₹ 2.5 per equity share of (₹ 1 each) amounting to ₹ 3982 lakhs for the year ended 31 March 2026 post shareholders' approval at the Annual General Meeting held on 26 August 2026.
11. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27 October 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at [www.jubilantingrevia.com](http://www.jubilantingrevia.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Jubilant Ingrevia Limited



Deepak Jain  
CEO & Managing Director

Place : Noida  
Date : 27 October 2026



**SIGNED FOR  
IDENTIFICATION  
PURPOSES**

